Omeros claims that its proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding inhibition of Factor XIa and kallikrein.
Omeros chairman and CEO Gregory Demopulos said that this is a good opportunity for Omeros and represents a potential life-saving treatment for patients.
"The ex vivo human and in-vivo animal efficacy data look strong, and the regulatory pathway is well-defined," Demopulos said.
"We have begun IND-enabling activities and are working to advance the program quickly to the clinic."